sábado, 28 de abril de 2018

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial | Orphanet Journal of Rare Diseases | Full Text

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial | Orphanet Journal of Rare Diseases | Full Text



Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial

  • Raphael SchiffmannEmail author,
  • Daniel G. Bichet,
  • Ana Jovanovic,
  • Derralynn A. Hughes,
  • Roberto Giugliani,
  • Ulla Feldt-Rasmussen,
  • Suma P. Shankar,
  • Laura Barisoni,
  • Robert B. Colvin,
  • J. Charles  Jennette,
  • Fred Holdbrook,
  • Andrew Mulberg,
  • Jeffrey P. Castelli,
  • Nina Skuban,
  • Jay A. Barth and
  • Kathleen Nicholls
Orphanet Journal of Rare Diseases201813:68
Received: 29 November 2017
Accepted: 18 April 2018
Published: 27 April 2018

Abstract

Background

Fabry disease is frequently characterized by gastrointestinal symptoms, including diarrhea. Migalastat is an orally-administered small molecule approved to treat the symptoms of Fabry disease in patients with amenable mutations.

Methods

We evaluated minimal clinically important differences (MCID) in diarrhea based on the corresponding domain of the patient-reported Gastrointestinal Symptom Rating Scale (GSRS) in patients with Fabry disease and amenable mutations (N = 50) treated with migalastat 150 mg every other day or placebo during the phase 3 FACETS trial (NCT00925301).

Results

After 6 months, significantly more patients receiving migalastat versus placebo experienced improvement in diarrhea based on a MCID of 0.33 (43% vs 11%; p = .02), including the subset with baseline diarrhea (71% vs 20%; p = .02). A decline in kidney peritubular capillary globotriaosylceramide inclusions correlated with diarrhea improvement; patients with a reduction > 0.1 were 5.6 times more likely to have an improvement in diarrhea than those without (p = .031).

Conclusions

Migalastat was associated with a clinically meaningful improvement in diarrhea in patients with Fabry disease and amenable mutations. Reductions in kidney globotriaosylceramide may be a useful surrogate endpoint to predict clinical benefit with migalastat in patients with Fabry disease.

Trial registration

NCT00925301; June 19, 2009.

Keywords

Amenable mutationDiarrheaFabry diseaseGastrointestinalGlobotriaosylceramideGSRSLyso-Gb3 MigalastatPharmacological chaperone

1 comentario:

  1. I found out, that taking herbal treatment is the best to get rid of HPV as soon as i feel the symptoms of HPV is appearing, i took the healing process by contacting Dr LUCKY for natural treatment, it works wonders and amazingly. Ever since I had the herbal treatment i have not feel these virus anymore and my doc told me the virus is gone, i am glad i finally got cured out from this disease. Any HPV or herpes patients should also get in touch with this herbalist Dr to get ride of any disease forever his Email Address: is drluckyherbalcure@gmail.com or wahtsapp +2348154637647

    ResponderEliminar